惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

小众软件
小众软件
C
Check Point Blog
Vercel News
Vercel News
Y
Y Combinator Blog
G
Google Developers Blog
P
Proofpoint News Feed
WordPress大学
WordPress大学
MongoDB | Blog
MongoDB | Blog
博客园 - 司徒正美
Last Week in AI
Last Week in AI
博客园 - 【当耐特】
N
Netflix TechBlog - Medium
L
LangChain Blog
V
V2EX
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
大猫的无限游戏
大猫的无限游戏
D
DataBreaches.Net
博客园_首页
B
Blog RSS Feed
The Cloudflare Blog
MyScale Blog
MyScale Blog
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
Microsoft Security Blog
Microsoft Security Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
SA Transcripts · 2026-05-13 · via All Articles on Seeking Alpha

Q1: 2026-05-12 Earnings Summary

EPS of -$0.20 beats by $0.03

 | 

Revenue of

$22.07M

(-2.02% Y/Y)

beats by $417.72K

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDT

Company Participants

Scott Schaper - Head of Investor Relations
Joel Becker - CEO, President & Director
Patrick Williams - Chief Financial Officer

Conference Call Participants

Michael Kratky - Leerink Partners LLC, Research Division
Priya Sachdeva - UBS Investment Bank, Research Division
Ross Osborn
Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division
Frank Takkinen - Lake Street Capital Markets, LLC, Research Division
Anthony Petrone - Mizuho Securities USA LLC, Research Division
Michael Polark - Wolfe Research, LLC

Presentation

Operator

Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the NeuroPace first quarter earnings call. [Operator Instructions]

Thank you. And I would now like to turn the conference over to Scott Schaper, Head of Investor Relations. You may begin.

Scott Schaper
Head of Investor Relations

Thank you, operator, and welcome to NeuroPace's First Quarter 2026 Earnings Conference Call. Our agenda begins with Joel Becker, NeuroPace's Chief Executive Officer, who will summarize our recent performance and strategic progress, followed by a detailed financial review and outlook from Patrick Williams, our Chief Financial Officer. Following our prepared remarks, we will open the call for questions.

Before we begin, I would like to remind you that certain statements made on today's call may constitute forward-looking statements within the meaning of federal securities laws. These statements include, among others, comments regarding our financial outlook for 2026, our commercial strategy, clinical and product development initiatives, regulatory matters, including our IGE PMA-Supplement and our expectations regarding operating performance and profitability.

Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. A discussion of these risks